No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1545-8. doi: 10.1016/j.pnpbp.2008.05.016. Epub 2008 May 29.

Abstract

Objective: This study investigated whether the brain-derived neurotrophic factor (BDNF) gene Val66Met single-nucleotide polymorphism (SNP) is associated with antipsychotic-induced tardive dyskinesia (TD) in schizophrenia.

Methods: Genotyping was performed for the BDNF gene Val66Met SNP in Korean schizophrenic patients with (n=83) and without TD (n=126) who were matched for antipsychotic drug exposure and other relevant variables.

Results: The frequencies of genotypes (chi2=2.37, p=0.306) and alleles (chi2=0.03, p=0.867) did not differ significantly between these two groups.

Conclusion: These findings suggest that the BDNF polymorphism does not play a major role in the susceptibility to TD in schizophrenic patients.

MeSH terms

  • Adult
  • Alleles
  • Amino Acid Substitution
  • Antipsychotic Agents / adverse effects
  • Brain-Derived Neurotrophic Factor / genetics*
  • Dyskinesia, Drug-Induced / genetics*
  • Female
  • Gene Frequency
  • Genotype
  • Humans
  • Male
  • Middle Aged
  • Mutation / physiology
  • Polymorphism, Genetic / genetics*
  • Schizophrenia / complications
  • Schizophrenia / drug therapy
  • Schizophrenia / genetics*

Substances

  • Antipsychotic Agents
  • Brain-Derived Neurotrophic Factor